Weight Management
Wegovy
Semaglutide · Solution for injection in pre-filled pen
A once-weekly GLP‑1 receptor agonist injection used for weight management, as set out in its product information.
- Partner pharmacy
- Personal assistance
- Discreet delivery
- Active ingredientSemaglutide
- FormPre-filled pen
- AdministrationSubcutaneous, once weekly
Shipping & Delivery
- Normally dispatched within 24 hours of payment confirmation.
- UPS Express · £12 · Approx. 7–9 business days
- Registered Mail · £8 · Approx. 14–20 business days
For research use only.
Not intended for human or animal consumption, nor for medical, personal or diagnostic use. By purchasing this product, you confirm that you are qualified to handle research materials.
What Wegovy is
Wegovy contains semaglutide, a GLP‑1 receptor agonist given as a once-weekly injection under the skin. The dose is increased gradually; suitability and dosing are decided by a prescriber on the basis of the approved product information.
GLP‑1 receptor agonist, at a weight-management dose
Semaglutide mimics GLP‑1, a gut hormone released after meals. It acts on areas of the brain that regulate appetite, increasing fullness and reducing hunger, and slows gastric emptying. When blood glucose is raised it also increases insulin release.
BrainLess hunger, more fullness, fewer cravings.
Gut and pancreasSlower gastric emptying; glucose-dependent insulin release.
In STEP 1, adults with overweight or obesity without diabetes lost an average of 14.9% of body weight over 68 weeks with semaglutide 2.4 mg, against 2.4% with placebo, alongside diet and physical activity.1 In SELECT, it reduced major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.2
Side effects and warnings
The most commonly reported side effects are gastrointestinal:
- Nausea, diarrhoea, vomiting, constipation and abdominal pain, mostly while the dose is being increased
- Gallbladder problems, including gallstones
- Dehydration from vomiting or diarrhoea, which can affect kidney function
- Very rarely, a condition of the optic nerve (NAION) causing sudden loss of vision has been reported with semaglutide; sudden changes in vision need urgent medical attention.3
ImportantSeek medical help promptly for severe, persistent abdominal pain, which may be a sign of pancreatitis. Not for use during pregnancy. Always read the patient information leaflet.
Product information
Common questions
Do I need a prescription?
Wegovy is a prescription-only medicine. After your request, the partner pharmacy verifies whether and how supply is possible, for example through an existing prescription or an assessment by an independent doctor where permitted.
How is it different from Ozempic?
Both contain semaglutide. Wegovy is authorised for weight management, with its own doses and product information; Ozempic is authorised for type 2 diabetes.
How is it different from Mounjaro?
Mounjaro contains tirzepatide, which acts on both the GIP and GLP‑1 receptors. Semaglutide acts on the GLP‑1 receptor only.
Why is the dose increased gradually?
Starting low and increasing step by step helps to reduce gastrointestinal side effects. The schedule is set out in the product information and is decided by the prescriber.
Do I pay when I send a request?
No. Payment is arranged individually with customer service once your request has been reviewed and can proceed.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- MHRA. Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION). Drug Safety Update, 5 February 2026.
- Wegovy: Summary of Product Characteristics. Novo Nordisk.
Related
Weight Management You may also be looking for
-
- Same active ingredient
